Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1996-02-16
1998-06-09
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
4284022, A61K 9127
Patent
active
057629587
ABSTRACT:
Liposomes are provided which contain ether lipids having the formula: ##STR1## as well as an underivatized phosphatidylethanolamine, a sterol, and a phosphatidylethanolamine-dicarboxylic acid headgroup-derivatized lipid. These liposomes are useful in a variety of therapeutic regimens, including the treatment of cancers and inflammatory disorders.
REFERENCES:
patent: 3752886 (1973-08-01), Munder et al.
patent: 4159988 (1979-07-01), Eibl et al.
patent: 4163748 (1979-08-01), Eibl et al.
patent: 4382035 (1983-05-01), Eibl
patent: 4734225 (1988-03-01), Eibl
patent: 4804789 (1989-02-01), Eibl
patent: 4920016 (1990-04-01), Allen et al.
patent: 4965391 (1990-10-01), Counsell et al.
patent: 4983397 (1991-01-01), Schroit
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5436234 (1995-07-01), Eibl
Mende, CA 110(23): 205219g.
Baker Int. J. Immunopharm 13, #4, p. 385, 1991.
Kucera AIDS Res. & Human Retroviruses 6 #4 p. 491 1990.
Bazill, et al., "Role of Endocytosis in the Action of Ether Lipids on WEHI-3B, HL60 and FEDCP-Mix A4 Cells", Cancer Res. 50: 7505 (1990).
Berdel, "Membrane-interactive lipids as experimental anticancer drugs", Br. J. Cancer 64: 208 (1991).
Berdel, "Ether Lipids and Derivatives as Investigational Anticancer Drugs", Onkologie 13: 245 (1990).
Bhatia, et al., "Sterospecific Systhesis of Antitumor Active Thioether PAF Analogs", Lipids 26(12): 1424 (1991).
Blume et al, "Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times" Biochim. Biophys. Acta. 1149: 180-184 (1993).
Daicho, et al., "Effects of alkyl glycosides incorporated into liposomes prepared from synthetic amphiphiles on their tissue distribution in Ehrlich solid tumor-bearing mice", BBA, 1107:61 (1992).
Darnell et al., Molecular Cell Biology, Scientific American Books, Inc. (1986), New York, pp. 573-575.
Deamer and Uster, "Liposome Preparation: Methods and Mechanisms," in: Liposomes (M. Ostro, ed.), Marcel Dekker, Inc., New York (1983), pp. 27-52.
Dietzfelbinger et al., "Removal of Breast Cancer Cells from Bone Marrow by in Vitro Purging with Ether Lipids and Cryopreservation", Cancer Res. 53: 3747 (1993).
Dive, et al., "Multiparametric Flow Cytometry of the Modulation of Tumore Cell Membrane Permeability by Developmental Antitumore Ether Lipid SRI 62-834 in EMT6 Mouse Mammary Tumor and HL-60 Human Promyelocytic Leukemia Cells", Cancer Res., 51:799 (1991).
Gabizon et al., "Prolongation of Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs", Pharm. Res. 10(5): 703 (1993).
Kaufmann-Kolle, et al., "Liposomal Hexadecylphosphocholine (HEPC): in Vitro and in Vivo Application", Chemical Abs. V4, 10.08.
Layton et al., "The Interaction of Liposomes with Cells: The Relation of Cell Specific Toxicity to Lipid Composition", Eur. J. Cancer 16: 64 (1980).
Lewis and McElhaney, "The Mesomorphic Phase Behavior of Lipid Bilayers," in The Structure of Biological Membranes (P. Yeagle, ed.), CRC Press, Inc. (1992), Boca Raton, Fl., pp. 73-155, at pp. 123-126.
Muschiol et al., "Alkyl Phosphocholine: Toxicity and Anticancer Properties", Lipids 22(11): 930 (1987).
Nairn, in: Remington's Pharmaceutical Science (A. Gennaro, ed)., Mack Publishing Co., Easton, PA, (1985), pp. 1492-1517.
Park et al., "Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo", Biochim. Biophys. Acta. 1108: 257 (1992).
Powis et al., "Selective Inhibition of Phophatidylinositol Phospholipase C by Cytotoxic Ether Lipid Analogues", Cancer Res. 52: 2835 (1992).
Powis et al., "The Cell Membrane and Cell Signals as Targets in Cancer Chemotherapy", Cancer Res. 50: 2203 (1990).
Reed et al., "Antineoplastic Ether-linked Phopholipid induces differentiation of acute myelogenous leukemic KG-1 cells into marcophase-like cells", Life Sci. 49: 1221 (1991).
Runge et al., "Destruction of Human Solid Tumors by Alkyl Lysophopholipids", JNCl. 64(6): 1301 (1980).
Tritton, et al., "How to Kill Cancer Cells: Membranes and Cell Signaling as Targets in Cancer Chemotherapy", Cancer Cells 2(4): 95 (1990).
Workman, "Antitumor Ether Lipids: Endocytosis as a Determinant of Cellular Sensitivity", Cancer Cells 3(8): 315 (1991).
Workman et al., "Plastelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-Methyl and SRIU 62-834 in HL-60 promyelocytic leukaemia cells", Biochem. Pharmacol. 41(2): 319 (1991).
Zeisig et al., "Antineoplastic activity in vitro of free and liposomal alkylphophocholines", Anti-Cancer Drugs 4: 57 (1993).
Ahmad Imran
Bhatia Suresh K.
Janoff Andrew S.
Mayhew Eric
Kishore Gollamudi S.
Rubin Kenneth B.
The Liposome Company Inc.
LandOfFree
Multilipid component ether lipid liposomes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multilipid component ether lipid liposomes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multilipid component ether lipid liposomes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2196062